OKYO Pharma Limited (OKYO) is a clinical-stage ophthalmology company developing urcosimod, a chemerin receptor (ChemR23) agonist, for neuropathic corneal pain (NCP) and dry eye disease. Because the company is pre-revenue, analysts value it primarily on the drug's potential, which produces an unusually wide target range.
Four verifiable, current analyst targets were reviewed: H.C. Wainwright (Yi Chen) at $5.00, reaffirmed in October 2026; Piper Sandler (Biren Amin) at $7.00, maintained in August 2026 after an Overweight initiation in February 2026; B. Riley Securities at $5.00, initiated in December 2025; and Lucid Capital at $13.00. The arithmetic mean is $7.50, with a range of $5.00 to $13.00. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The dispersion reflects different assumptions rather than disagreement on direction. All four ratings are bullish, but H.C. Wainwright trimmed its target from $7.00 to $5.00 in mid-2026 while keeping its Buy rating, and Piper Sandler bases its $7.00 target on a discounted cash flow model assuming roughly $328 million in peak risk-adjusted urcosimod sales. Lucid Capital's $13.00 target is notably higher, underscoring how sensitive these valuations are to approval probability and market-size assumptions.
As of late October 2026, OKYO traded around $1.49, with a 52-week range of roughly $1.26 to $3.20 and a market capitalization near $78 million. Reaching $7.50 would require approximately 400% appreciation, a very large move that would effectively re-rate the company from a small-cap biotech to a materially more valuable late-stage pipeline story.
The path runs almost entirely through clinical and regulatory milestones. OKYO has begun enrolling patients in NEPTUNE, a registrational Phase 3 study of urcosimod in NCP, and management has said the FDA's feedback validated the trial design and regulatory path. With no approved treatment for NCP, positive data could be transformative; negative data could sharply reset expectations.
OKYO has traded below its 200-day average near $1.65 and near its 50-day average around $1.44, reflecting weak momentum after a decline from the January 2026 high near $3.20. The $1.26-$1.30 zone marks the 52-week low and a key support area, while $1.50-$1.65 and the prior high near $3.20 are notable overhead levels. A sustained move through the $1.65 area could signal improving sentiment, but the shares remain a low-volume, micro-cap trading vehicle.
Analyst price targets generally reflect a research horizon of roughly 12 months, though the individual reports reviewed here do not all state an identical period, and biotech targets are especially tied to discrete data events rather than calendar time. The most important near-term items are NEPTUNE enrollment progress, any topline or interim clinical data readouts, additional regulatory feedback, cash position and financing announcements, and analyst target revisions. Earnings are less meaningful for a pre-revenue company than clinical news flow.
For traders tracking names like OKYO, I find Tickeron's AI Daily Buy/Sell Signals helpful for monitoring shifting conditions. The system uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. I use these signals to discover opportunities, keep an eye on existing positions, and spot emerging trend changes more efficiently alongside my own research.
The $7.50 central target is the average of four bullish analyst price targets spanning $5.00 to $13.00, and it sits roughly 400% above the recent price near $1.49, making it a very large required move. Support comes from urcosimod's first-mover position in neuropathic corneal pain, encouraging Phase 2 data, and FDA alignment on the Phase 3 path. The principal obstacles are clinical-trial risk, continued cash burn and dilution, and the wide spread among analyst estimates that reflects genuine uncertainty about the drug's commercial value. Whether OKYO approaches the target depends overwhelmingly on upcoming clinical and regulatory milestones rather than near-term earnings. The target is a benchmark for what analysts believe the pipeline could be worth under favorable assumptions, not a guarantee of future performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OKYO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 38 instances where the indicator turned negative. In 35 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OKYO as a result. In 70 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
OKYO moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OKYO crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 70%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OKYO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for OKYO entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +10.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where OKYO advanced for three days, in 130 of 151 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
OKYO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. OKYO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.381) is normal, around the industry mean (3.592). P/E Ratio (-3.837) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology